Want to see JP:4579 full AI Analyst Report?
4579 Stock Chart & Stats
¥1010.00
-¥6.00(-1.49%)
At close: 4:00 PM EST
¥1010.00
-¥6.00(-1.49%)
Day’s Range― - ―
52-Week Range¥438.00 - ¥1,465.00
Previous CloseN/A
Volume117.60K
Average Volume (3M)135.35K
Market Cap
¥14.11B
Enterprise Value¥10.30K
Total Cash (Recent Filing)¥4.70B
Total Debt (Recent Filing)¥2.69B
Price to Earnings (P/E)62.6
Beta1.00
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.95
Shares Outstanding26,031,412
10 Day Avg. Volume103,220
30 Day Avg. Volume135,353
Financial Highlights & Ratios
PEG Ratio-0.58
Price to Book (P/B)3.47
Price to Sales (P/S)6.01
P/FCF Ratio-56.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)48.4
Revenue Forecast (FY)¥4.59B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthRevenue growth of 20.6% indicates improved partnering, licensing or collaboration activity. Sustained top-line expansion would broaden the base for milestone and royalty income, although the pack does not identify product-level contributors.
High Gross MarginsTTM results returned to profitability with roughly 79% gross margin and 9% operating margin. This high-margin profile supports an asset-light drug-discovery model, giving successful programs meaningful contribution potential.
Balance Sheet StrengthEquity of about ¥7.8B against ¥11.0B of assets and debt-to-equity near 0.34 provide financial capacity to fund research and absorb development uncertainty. The stronger equity base can support partnering through clinical milestones.
Bears Say
Volatile ProfitabilityProfitability has not normalized: losses occurred in 2023–2024, while TTM net margin was about 4% and below 2025 profitability. Such uneven earnings make durable planning harder and increase dependence on successful licensing milestones.
Inconsistent Cash GenerationOperating cash flow was negative in 2023 and 2025 before recovering to roughly ¥0.5B TTM; free cash flow followed the same pattern. This volatility suggests internal funding capacity can vary materially across development cycles.
Low Returns On EquityAlthough leverage is manageable, debt has risen materially versus 2021–2022 and TTM ROE is only about 2%. Limited returns on the equity base could constrain reinvestment efficiency and make future financing more important if development spending increases.
RaQualia Pharma Inc. News
4579 FAQ
What was RaQualia Pharma Inc.’s price range in the past 12 months?
RaQualia Pharma Inc. lowest stock price was ¥438.00 and its highest was ¥1465.00 in the past 12 months.
What is RaQualia Pharma Inc.’s market cap?
RaQualia Pharma Inc.’s market cap is ¥14.11B.
When is RaQualia Pharma Inc.’s upcoming earnings report date?
RaQualia Pharma Inc.’s upcoming earnings report date is Nov 06, 2026 which is in 52 days.
How were RaQualia Pharma Inc.’s earnings last quarter?
RaQualia Pharma Inc. released its earnings results on Aug 14, 2026. The company reported -¥9.26 earnings per share for the quarter.
Is RaQualia Pharma Inc. overvalued?
According to Wall Street analysts RaQualia Pharma Inc.’s price is currently Overvalued.
Does RaQualia Pharma Inc. pay dividends?
RaQualia Pharma Inc. does not currently pay dividends.
What is RaQualia Pharma Inc.’s EPS estimate?
RaQualia Pharma Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RaQualia Pharma Inc. have?
RaQualia Pharma Inc. has 26,031,412 shares outstanding.
What happened to RaQualia Pharma Inc.’s price movement after its last earnings report?
RaQualia Pharma Inc. reported an EPS of -¥9.26 in its last earnings report. Following the earnings report the stock price went down -0.775%.
Which hedge fund is a major shareholder of RaQualia Pharma Inc.?
Currently, no hedge funds are holding shares in JP:4579
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
RaQualia Pharma Inc.
RaQualia Pharma Inc., established in 2008 and based in Nagoya, Japan, is a pharmaceutical company dedicated to the global research and development of innovative drug compounds. Its human therapeutic pipeline features several key candidates. Tegoprazan, designed to treat gastroesophageal reflux disease (GERD), is currently undergoing Phase 1 clinical trials in the United States. Grapiprant is in Phase II development in the U.S. and Phase I in China for pain management; it is also being investigated in Phase I studies in both the U.S. and China for its potential in cancer therapy. Beyond human medicines, RaQualia Pharma develops a range of veterinary products. These include grapiprant for managing osteoarthritis in dogs, a ghrelin receptor agonist aimed at addressing cancer-related anorexia/cachexia syndrome and constipation stemming from spinal cord injury, and ELURA, a medication for combating weight loss in cats suffering from chronic kidney disease. The company's extensive R&D pipeline also covers various other therapeutic areas. This includes a TRPM8 blocker for neuropathic pain, a motilin receptor agonist targeting gastrointestinal motility disorders such as gastroparesis, functional dyspepsia, and post-operative ileus, and a potassium-competitive acid blocker for GERD, which has successfully concluded Phase 1 clinical trials. Further early-stage developments encompass a 5-HT4 partial agonist for gastroparesis, functional dyspepsia, and chronic constipation; a 5-HT2B antagonist for irritable bowel syndrome with diarrhea; EP4 antagonists for canine pain management and, in separate Phase I trials, for cancer and general pain indications; a serotonin 5-HT2A and dopamine D2 receptor blocker for schizophrenia; a Cyclooxygenase-2 inhibitor (Phase I for pain); a CB2 agonist; a selective sodium channel blocker; a P2X7 receptor antagonist (Phase I for neuropathic pain); and a retinoic acid receptor alpha agonist. To further its research and development initiatives, RaQualia maintains strategic partnerships with Interprotein Corporation, ASKA Pharmaceutical Co., Ltd., and Epigeneron, Inc.